| Title | Anticholinergics for the treatment of benign prostatic hyperplasia: from a contraindication to an indication | |
| Authors | A. Athanasopoulos, K. Gyftopoulos, K. Giannitsas, G. Lazaridis, S. Deirmentzoglou and P. Perimenis
Section of Urodynamic Urology, Department of Urology, School of Medicine, University of Patras, Patras, Greece |
|
| Citation | Athanasopoulos, A., Gyftopoulos, K., Giannitsas, K., Lazaridis, G., Deirmentzoglou, S. et al: Anticholinergics for the treatment of benign prostatic hyperplasia: from a contraindication to an indication, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 137-139 (2006) | |
| Publication Date | Accepted for publication: 19-20 May 2006 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Anticholinergics, benigne prostatic hyperplasia, overactive bladder, tolterodine, tamsulosine. | |
| Other Terms | review article | |
| Summary | The aim of this study was to evaluate the effect of tolterodine in combination with an α-blocker (tamsulosin) on the quality of life in patients with symptomatic Prostatic Benign Hyperplasia (BPH) and concomitant detrusor overactivity (DOA). Fifty consecutive patients with urodynamically proven mild or moderate symptomatic BPH and concomitant DOA were included. All patients were initially treated with Tamsulosin 0.4 mg OD p.o. One week later, patients were randomly allocated in two groups: Group A (n=25) continued initial treatment, while Group B (n=25) received additionally Tolterodine 2 mg TD p.o. Re-evaluation with the UROLIFE QoL questionnaire and urodynamic study was performed three months later. Analysis revealed a statistically significant improvement in QoL scores only in Group B patients (mean score 525.0 and 628.4 pre- and post-treatment, respectively, 2-sided t- test, p=0.0003). A significant difference was noted in both groups post-treatment for maximum flow rate and volume at first contraction. Additionally, in Group B a statistically significant difference was observed for maximum detrusor pressure and pressure of maximum unstable contraction post-treatment. Concluding, from the patient’s perspective, the addition of Tolterodine is an effective and relatively safe option in the management of the bothersome symptoms associated with BPH and DOA. The proposed combination of an a1-blocker with an anticholinergic for the treatment of BPO and concomitant DOA is promising. | |
| References | 1. Garraway W.M., Collins G.N., Lee R.J.: High prevalence of benign prostatic hypertrophy in the community. Lancet 338: 469 (1991)
2. Speakman M.J.: Initial choices and final outcomes in lower urinary tract symptoms. Eur. Urol. 40 (suppl 4): 21 (2001) 3. Peters T.J., Donovan J.L., Kay H.E., Abrams P., de la Rosette J.J., Porru D., Thuroff J.W.: The International Continence Society Benign Prostatic Hyperplasia study: the bothersomeness of urinary symptoms. J. Urol. 157: 885 (1997) 4. Rosier P.F.W.M., de la Rosette J.J.M.C.H., Wijkstra H., Van Kerrebroeck Ph.E.V., Debruyne F.M.J.: Is detrusor instability in elderly males related to the grade of obstruction? Neurourol. Urodyn. 14: 625 (1995) 5. Stoevelaar H.J., Van de Beek C., Casparie A.F., McDonnel J., Nijs H.G.: Treatment choice for benign prostatic hyperplasia: A matter of urologic preference? J. Urol. 161: 133 (1999) 6. Schafer W., Waterbar F., Langen P.H., Deutz F.G.: A simplified graphical procedure for detailed analysis of detrusor and outlet function during voiding. Neurourol. Urodyn. 8: 405 (1989) 7. Lukacs B., Comet D., Grange J.C., Thibault P.: Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. Br. J. Urol. 80: 722 (1997) 8. Schulman C.C.: Long-term aspects of medical treatment of BPH. Eur. Urol. 40 (suppl 3): 8 (2001) 9. Michel M.C., de la Rossete J.J.: Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert. Opin. Pharmacother. 5: 151-160 (2004) 10. Michel M.C.: Potential role of α1-adrenoreceptor subtypes in the etiology of LUTS. Eur. Urol. Suppl. 1: 5-13 (2002) 11. Perlberg S., Caine M. Adrenergic response of bladder muscle in prostatic obstruction. Its relation to detrusor instability. Urology 20: 524-527 (1982) 12. Price D.: Potential mechanisms of action of superselective alpha(1)-adrenoreceptor antagonists. Eur. Urol. 40 (Suppl 4): 5-11 (2001) 13. Anderson K.E., Yoshida M.: Antimuscarinics and the over- active detrusor – which is the main mechanism of action? Eur. Urol. 43: 1-5 (2003) 14. Abrams P., Kaplan S., Millard R. Safety of tolterodine in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity. Eur. Urol. (Suppl 1): 520 (2002) 15. Saito H., Yamada T., Oshima H., et al.: A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn. J. Urol. Surg. 8: 525-536 (199 |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|